These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26595521

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Anticancer effect of 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin: in vitro and in vivo].
    Li L, Liu H, Zhang SH, Hu L, Zhen YS.
    Yao Xue Xue Bao; 2013 Dec; 48(12):1771-7. PubMed ID: 24689233
    [Abstract] [Full Text] [Related]

  • 23. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
    Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, Moriwaki H, Kozawa O.
    Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P, Dolatabadi S, Svec D, Jonasson E, Safavi S, Andersson D, Grundevik P, Thomsen C, Ståhlberg A.
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A role of Rab7 in stabilizing EGFR-Her2 and in sustaining Akt survival signal.
    Wang T, Zhang M, Ma Z, Guo K, Tergaonkar V, Zeng Q, Hong W.
    J Cell Physiol; 2012 Jun; 227(6):2788-97. PubMed ID: 21928319
    [Abstract] [Full Text] [Related]

  • 29. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
    Ghadban T, Jessen A, Reeh M, Dibbern JL, Mahner S, Mueller V, Wellner UF, Güngör C, Izbicki JR, Vashist YK.
    Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
    [Abstract] [Full Text] [Related]

  • 30. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.
    Oncogene; 2011 Jun 02; 30(22):2581-6. PubMed ID: 21258415
    [Abstract] [Full Text] [Related]

  • 31. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
    Ranji P, Jonasson E, Andersson L, Filges S, Luna Santamaría M, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A.
    J Transl Med; 2024 Apr 26; 22(1):389. PubMed ID: 38671504
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M, Andersson MK, Forni C, Ståhlberg A, Andersson C, Olofsson A, Mantovani R, Aman P.
    Oncogene; 2009 Jan 15; 28(2):270-8. PubMed ID: 18850010
    [Abstract] [Full Text] [Related]

  • 34. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T, Lowell AM, Engelman JA, Shapiro GI.
    Cancer Res; 2005 Jul 15; 65(14):6401-8. PubMed ID: 16024644
    [Abstract] [Full Text] [Related]

  • 35. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, Schirmacher P, Kern MA, Chiosis G, Rieker RJ.
    Clin Cancer Res; 2011 Apr 15; 17(8):2237-49. PubMed ID: 21372220
    [Abstract] [Full Text] [Related]

  • 36. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 37. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
    Hirakawa H, Fujisawa H, Masaoka A, Noguchi M, Hirayama R, Takahashi M, Fujimori A, Okayasu R.
    Cancer Med; 2015 Mar 15; 4(3):426-36. PubMed ID: 25582113
    [Abstract] [Full Text] [Related]

  • 38. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
    Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, Tamm KP.
    Exp Cell Res; 2013 Mar 10; 319(5):600-11. PubMed ID: 23246572
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 40. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y, Ou W, Meng F, Zhou H, Wang A.
    Mol Cancer; 2011 Sep 30; 10():125. PubMed ID: 21962244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.